Prostate Cancer Prevention Trial identifies men most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.

Prostate cancer education is key for patient decision-making

Prostate cancer education is key for patient decision-making

Researchers found that men who aren't well educated about prostate cancer have more difficulty making decisions.

Prostate cancer risk cut by tomatoes

Prostate cancer risk cut by tomatoes

Men who eat more than 10 portions of tomatoes each week have an 18% lower risk of developing prostate cancer.

Upgraded Prostate Cancer Risk Calculator 2.0, with emojis, is available online

A calculator to help men and their doctors assess the risk of prostate cancer has had a major upgrade to enhance men's and their physicians' understanding of a man's risk of prostate cancer.

Men in prostate cancer prevention trial more likely to undergo biopsy

Men in prostate cancer prevention trial more likely to undergo biopsy

Men without prostate cancer taking part in the trial who participate in other aspects are most likely to undergo a challenging biopsy.

Lasting drop in prostate cancer mortality with prostate-specific antigen (PSA)

Lasting drop in prostate cancer mortality with prostate-specific antigen (PSA)

Prostate-specific antigen (PSA) screening is associated with a lasting reduction in prostate cancer mortality, according to a study published online.

Genomic analysis of prostate cancer suggests best plan after surgery

A genomic tool can help doctors and patients make a more informed decision on the need for radiation therapy after surgery for prostate cancer.

Prior diagnosis of depression worsens outcomes in prostate cancer

Prior diagnosis of depression worsens outcomes in prostate cancer

Men with diagnosed depressive disorders are less likely to pursue definitive treatment options for prostate cancer and more likely to have poorer outcomes.

Robot-assisted surgery for prostate cancer controls disease for 10 years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study.

Tips for Patients and Their Partners for Restoring Intimacy after Prostate Cancer

Tips for Patients and Their Partners for Restoring Intimacy after Prostate Cancer

Although their lives eventually return to normal after treatment, some men have to cope with lingering effects of their treatment that affects their libido or sexual function. Daniel Watter, EdD, offers guidance tips to share with patients who are surviving prostate cancer that can help them through the recovery process.

New epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer

Two independent trials have validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.

Genetics is the dominant risk factor for familial breast, prostate, and colorectal cancers

Genetics is the dominant risk factor for familial breast, prostate, and colorectal cancers

A study of people who were adopted identified genetics as the dominant risk factor in familial breast, prostate, and colorectal cancers.

Vasectomy may increase risk of aggressive prostate cancer

Vasectomy may increase risk of aggressive prostate cancer

Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer, according to a new study.

Obtaining 16 cores is better than obtaining 12 cores for prostate cancer detection

Obtaining 16 cores is better than obtaining 12 cores for prostate cancer detection

A research team from Japan found that 16-core biopsy has a slightly higher detection rate than 12-core biopsy.

Bike riding may up prostate cancer risk

Bike riding may up prostate cancer risk

Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.

Rates of observation as prostate cancer management vary

Rates of observation as prostate cancer management vary

Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.

Robot-assisted surgery effective in controlling prostate cancer for 10 years

Robot-assisted surgery effective in controlling prostate cancer for 10 years

Results of a new study show that robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years.

Link between vasectomy and prostate cancer greater in high-grade cases

Link between vasectomy and prostate cancer greater in high-grade cases

Vasectomy is associated with an increased incidence of prostate cancer overall during extended follow-up, with an elevated risk seen for high-grade and lethal cancer.

Depressed men with prostate cancer have worse outcomes

Depressed men with prostate cancer have worse outcomes

Depressed men with a diagnosis of intermediate- or high-risk prostate cancer have worse overall outcomes.

Doctors steer prostate cancer treatment choices

Doctors steer prostate cancer treatment choices

Physicians who diagnosed low-risk prostate cancer had more influence over the decision to enter active surveillance than did the disease characteristics, according to a case review.

Radiation-induced toxicity risk in prostate cancer predicted by variations in key gene

Key genetic variants may affect how cancer patients respond to radiation treatments, according to a new study.

Researchers Identify New Cancer Metastasis-Suppressor Gene

Researchers Identify New Cancer Metastasis-Suppressor Gene

Researchers searching for a target that would interfere with cancer metastasis identified a new suppressor of metastasis that may lead toward the development of more effective treatments for prostate cancer and other malignant solid tumors.

Hypnosis Relaxation May Help Men Experiencing Hot Flashes After Prostate Cancer

Hypnosis Relaxation May Help Men Experiencing Hot Flashes After Prostate Cancer

Hot flashes are a common side effect of menopausal changes experienced by women; however, they can also be a hormone-related effect experienced by men with prostate cancer.

Study Results Demonstrate A New Prostate Cancer Treatment

Study Results Demonstrate A New Prostate Cancer Treatment

A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.

Study Shows How Tumors Remodel Their Surroundings to Grow

Study Shows How Tumors Remodel Their Surroundings to Grow

The loss of the p62 protein in tumor cells and the surrounding tissue can enhance the growth and progression of tumors, according to research from Sanford Burnham Medical Research Institute. The findings add to the acknowledgement that the stroma is an integral part of cancer initiation, growth, and expansion.

Prostate cancer specialists' recommendations favor their own treatments

Prostate cancer specialists' recommendations favor their own treatments

Specialists who treat prostate cancer agree that active surveillance is an effective option for patients with low-risk prostate cancer; however, most are more likely to recommend the treatment provided by their own specialties.

Enzalutamide Improves Survival in Patients with Advanced Prostate Cancer

Enzalutamide Improves Survival in Patients with Advanced Prostate Cancer

In an international randomized phase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy.

Active surveillance for low-risk prostate cancer underused

Active surveillance for low-risk prostate cancer underused

Although most prostate cancer specialists believe active surveillance to be effective and underused, fewer endorse active surveillance than other therapies for low-risk prostate cancer.

Unique PET agent traces treatment-resistant prostate cancer

A groundbreaking molecular imaging agent has been developed to help clinicians find as much prostate cancer as possible and determine whether it is responding favorably or not.

Specialists prefer treatments over surveillance for low-risk prostate cancer

Specialists prefer treatments over surveillance for low-risk prostate cancer

Specialists who treat prostate cancer agree that active surveillance is an effective option—yet according to a study most don't recommend it when appropriate for their own patients.

Prostate-cancer surgery prices vary widely

Prostate-cancer surgery prices vary widely

A study from the University of Iowa examined the charge for prostate cancer surgery at 100 hospital all over the United States, and the results showed widely different prices.

Apoptotic Death of Prostate Cancer Cells by a GnRH-II Antagonist

Apoptotic Death of Prostate Cancer Cells by a GnRH-II Antagonist

Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. Here, we investigated the effect of SN09-2 on the growth of PC3 prostate cancer cells.

The importance of patient education in prostate cancer care

The importance of patient education in prostate cancer care

Male patients with prostate cancer, and patients with other genitourinary cancers, need information on how their cancer and its treatment will affect their life.

Prostate cancer biomarkers identified in seminal fluid

Improved diagnosis and management of prostate cancer could result from research that has discovered that seminal fluid contains biomarkers for the disease.

New care guidelines issued for prostate cancer survivors

New care guidelines issued for prostate cancer survivors

New guidelines have been developed for clinical follow-up care for prostate cancer survivors. Issues addressed include health promotion, surveillance for recurrence, and new primaries.

ACS Releases Long-Term Primary Care Guidelines for Prostate Cancer Survivors

ACS Releases Long-Term Primary Care Guidelines for Prostate Cancer Survivors

The American Cancer Society released a set of guidelines addressing the long-term primary care for survivors of prostate cancer. The guidelines outline follow-up care, monitoring for recurrence, and screening for secondary primary cancers. They also reiterate the need to educate survivors about physical exercise and smoking cessation.

Enzyme from antidepressants may aid in developing prostate cancer treatments

An enzyme commonly used as a target for antidepressants may also promote prostate cancer growth, according to an international team of scientists.

MR fusion guided prostate biopsy: A new way to detect prostate cancer

MR fusion guided prostate biopsy: A new way to detect prostate cancer

A new screening technique, MR fusion guided prostate biopsy, holds promise for increased prostate cancer detection.

Prolaris test predicts prostate cancer mortality risk

The Prolaris test distinguished newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower risk disease.

Biomarkers in seminal fluid indicate presence and severity of prostate cancer

Biomarkers in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of prostate cancer could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

Prostate cancer treatment can delay chemotherapy

Prostate cancer treatment can delay chemotherapy

Researchers have developed a new technique to combat metastatic prostate cancer (which is called castration-resistant), which could delay the start of chemotherapy.

Sexually transmitted infection linked to prostate cancer

Sexually transmitted infection linked to prostate cancer

Many people are unaware that prostate cancer may sometimes be transmitted sexually.

Circumcision may lower prostate cancer risk

Circumcision may lower prostate cancer risk

Circumcision appears to confer a protective effect against the development of prostate cancer, according to research published online.

Antidepressants may slow prostate cancer growth

Antidepressants may slow prostate cancer growth

There's new evidence that certain drugs used to treat depression might also help stop the growth of prostate cancer.

ASCO: New drug effective for metastatic prostate cancer

ASCO: New drug effective for metastatic prostate cancer

Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.

Informed consent plays large in prostatectomy litigation

Informed consent plays large in prostatectomy litigation

Claims of not receiving proper informed consent and clinical performance are the main issues that arise in radical prostatectomy malpractice lawsuits.

Docetaxel + ADT ups survival in metastatic prostate cancer

Docetaxel + ADT ups survival in metastatic prostate cancer

Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.

Metastatic tumor sites predict OS in castration resistant prostate cancer

Metastatic tumor sites predict OS in castration resistant prostate cancer

The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.

Aggressive treatment doesn't benefit older, sicker men with early-stage prostate cancer

Treating older men with early stage prostate cancer who also have other serious health problems with aggressive therapies does not help them live longer and, in fact, can be detrimental.

Epigenetic test for prostate cancer markers valuable

Epigenetic test for prostate cancer markers valuable

A commercial test designed to rule out the presence of genetic biomarkers of prostate cancer could exclude the need for repeat prostate biopsies in many patients.

Targeted biopsies may trigger prostate cancer reclassification

Targeted biopsies may trigger prostate cancer reclassification

Targeted prostate biopsy using multi-parametric magnetic resonance imaging-ultrasound fusion may lead to reclassification of prostate cancer that was initially diagnosed as low-risk, according to research.

Vitamin D deficiency may have ties to aggressive prostate cancer

Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in men who underwent their first prostate biopsy because of abnormal PSA test and/or DRE results.

Survival benefit associated with aggressive prostate cancer treatment weakens with comorbidity

Survival benefit associated with aggressive prostate cancer treatment weakens with comorbidity

For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study.

Electronic nose sniffs out prostate cancer in urine samples

A novel noninvasive technique can detect prostate cancer using an electronic nose.

Comparisons across tumors improve identification of cancer-associated genes from microarrays

A new gene expression analysis approach for identifying cancer genes challenges the current paradigm of microarray data analysis.

Model predicts therapy outcomes for prostate cancer with bone metastasis

A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients.

Low testosterone may indicate worsening of low-risk prostate cancer

For men with low-risk prostate cancer, low levels of testosterone may indicate a worsening of their disease, concluded a new study.

Chronic inflammation may be linked to aggressive prostate cancer

The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer.

Electronic nose distinguishes prostate cancer from BPH

Electronic nose distinguishes prostate cancer from BPH

The ChemPro 100-electronic nose can discriminate prostate cancer from benign prostatic hyperplasia using urine headspace, according to a study.

Low testosterone level may entail prostate cancer reclassification

Low testosterone level may entail prostate cancer reclassification

Men under active surveillance for prostate cancer who have reductions in testosterone levels may be at increased risk for disease reclassification, according to research.

New target for prostate cancer resistant to hormone therapies

A protein called BET bromodomain protein 4 binds to the androgen receptor downstream of where current therapies work, where it targets androgen receptor signaling. This new study suggests a way to block hormones, since prostate cancer that becomes resistant to current treatments might remain sensitive to a drug that targets BET bromodomain proteins.

Preventing radiotherapy-associated sexual dysfunction in prostate cancer

Preventing radiotherapy-associated sexual dysfunction in prostate cancer

Sexual dysfunction is a common and distressing side effect of prostate cancer treatment. Two new reports from randomized clinical trials offer mixed results for adjuvant pharmacotherapy intended to prevent erectile dysfunction in men undergoing radiotherapy for prostate cancer.

Six months hormone therapy plus radiation therapy improves prostate cancer survival

Men with prostate cancer that is small and confined to the prostate gland but at risk of growing, do better if they are treated with radiotherapy combined with androgen deprivation therapy.

Lack of vitamin D may increase risk of aggressive prostate cancer

Lack of vitamin D may increase risk of aggressive prostate cancer

Severe vitamin D deficiency linked with higher grade and stage of prostate tumors, according to research.

Multiparametric MRI accurately detects prostate cancer

Multiparametric MRI accurately detects prostate cancer

Multiparametric MRI is highly accurate for the detection of prostate cancer in patients with clinically low-risk cancer; accuracy is highest with larger cancer volume and higher Gleason grade.

Survey offers insight on coping with advanced prostate cancer

Survey offers insight on coping with advanced prostate cancer

Ninety-one men and 100 caregivers shared their thoughts on what worries them most when advanced prostate cancer becomes a way of life.

Blood-based biomarker may determine enzalutamide resistance in prostate cancers

Blood-based biomarker may determine enzalutamide resistance in prostate cancers

Men with metastatic, castration-resistant prostate cancer who started treatment with enzalutamide and had the molecule AR-V7 present in CTCs obtained prior to treatment had a worse response to enzalutamide.

Chronic prostate inflammation associated with prostate cancer

Chronic prostate inflammation associated with prostate cancer

The presence of chronic inflammation in benign prostate tissue samples is associated with prostate cancer, especially high-grade disease, according to a study.

Adherence rates for prostate cancer quality of care measures low

Adherence rates for prostate cancer quality of care measures low

Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation.

Primary androgen deprivation ineffective for most early prostate cancer

In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.

Molecular test prompts changes in prostate cancer treatment plans

The PROCEDE 500 study demonstrated that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.

Bone turnover markers predict prostate cancer outcomes

Bone turnover markers predict prostate cancer outcomes

Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).

Younger men benefit most from surgery for localized prostate cancer

Younger men benefit most from surgery for localized prostate cancer

A new study found substantial long-term reduction in mortality for men with localized prostate cancer who undergo a radical prostatectomy.

PADT does not lower mortality for localized prostate cancer

PADT does not lower mortality for localized prostate cancer

For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival for the majority of men who have not received treatment with curative intent.

Patients desire specific prostate cancer information

Patients desire specific prostate cancer information

Although patients with prostate cancer endorse multiple sources of information, they report greatest satisfaction with information from the treating physician about patient outcomes.

Prostatectomy lowers early prostate cancer mortality

Prostatectomy lowers early prostate cancer mortality

Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.

Robot-assisted prostatectomy yields improved surgical margins

Robot-assisted prostatectomy yields improved surgical margins

Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.

Key cellular pathway in prostate cancer identified

The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.

Genetic mutation in prostate cancer linked to later aggressive cancer

Genetic mutation in prostate cancer linked to later aggressive cancer

A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.

3D mapping biopsy finds 3x more prostate cancer than ultrasound biopsy

Three-dimensional biopsies find more prostate cancers, particularly in the anterior regions, than those guided by ultrasound, according to a new clinical study.

Key gene inhibits prostate cancer metastasis

Key gene inhibits prostate cancer metastasis

New evidence lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.

Multiple biopsies increase infection risk for prostate cancer patients

Multiple biopsies increase infection risk for prostate cancer patients

Men with prostate cancer on active surveillance should be informed of the risk of complications linked to repeated biopsies.

Prognostic test modifies treatment decisions for prostate cancer patient

Prognostic test modifies treatment decisions for prostate cancer patient

Results from PROCEDE 500, a clinical utility study with the Prolaris test, demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.

Why exercise improves prostate cancer outcomes

Why exercise improves prostate cancer outcomes

Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes.

ASCO: Enzalutamide effective for metastatic prostate cancer

ASCO: Enzalutamide effective for metastatic prostate cancer

Two beneficial treatment approaches are available for metastatic and locally advanced prostate cancer, according to two studies presented in advance of ASCO's annual Genitourinary Cancers Symposium.

Too soon to say if soy is a promising ­adjuvant for radiotherapy

Too soon to say if soy is a promising ­adjuvant for radiotherapy

Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.

Additional prostate cancer criteria may help ID surveillance candidates

Additional prostate cancer criteria may help ID surveillance candidates

Additional predictors guide selection of patients with prostate cancer for active surveillance programs.

AACR: Exercise improves vessel shape in prostate cancer

AACR: Exercise improves vessel shape in prostate cancer

Brisk walking before prostate cancer diagnosis has been associated with more regularly-shaped blood vessels.

Nomogram determines individualized estimates of screen-detected prostate cancer overdiagnosis

Nomogram determines individualized estimates of screen-detected prostate cancer overdiagnosis

Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated.

AACR: Higher melatonin levels tied to lower prostate cancer risk

AACR: Higher melatonin levels tied to lower prostate cancer risk

After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin demonstrated a significantly lower prostate cancer risk.

Pain drugs used during prostate gland removal linked to cancer outcome

The methods used to anesthetize patients with prostate cancer and control pain due to surgical resection of the prostate glands for adenocarcinoma may affect patients' long-term cancer outcomes, a study has found.

Early BPA exposure may increase later prostate cancer risk

Early BPA exposure may increase later prostate cancer risk

In vivo BPA exposure has been tied to increased incidence of prostate intraepithelial neoplasia and adenocarcinoma.

Prostate cancer biomarker may predict patient outcomes

A cell-surface protein called CD151 may serve as a biomarker that accurately predicts which patients with prostate cancer are likely to experience metastasis or recurrence.

Coordinated approach is needed for castrate-resistant prostate cancer

With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.

Neuraxial plus general anesthesia may improve prostate CA outcomes

Neuraxial plus general anesthesia may improve prostate CA outcomes

Supplementing general anesthesia (GA) with neuraxial anesthesia during prostate cancer surgery is associated with improved oncological outcomes compared with GA alone.

Integrated care optimal for castration-resistant prostate cancer

Framework for optimizing CRPC treatment should involve joint management by both a urologist and a medical oncologist.

Protein in prostate biopsies signals increased risk of cancer

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.

Statins lower risk of dying from prostate cancer

Men with prostate cancer who take the cholesterol-lowering drugs known as statins are significantly less likely to die from their cancer than men who do not take such medication, according to a new study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs